Advertisement

Document › Details
Kiadis Pharma N.V.. (3/13/18). "Press Release: Kiadis Pharma Raises €23.4 Million in a Private Placement of 2.6 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other Jurisdiction in which Unlawful]". Amsterdam.
Original document
accessed by [iito] on 2018-03-28
Record changed: 2018-03-31 |
Advertisement

More documents for Kiadis (Group)
- [1] Kiadis Pharma N.V.. (10/12/18). "Press Release: Kiadis Pharma Provides Regulatory and Clinical Update on ATIR101". Amsterdam....
- [2] Kiadis Pharma N.V.. (8/1/18). "Press Release: Kiadis Pharma Secures €20 Million Debt Financing Facility from Kreos Capital". Amsterdam....
- [3] Kiadis Pharma N.V.. (3/28/18). "Press Release: Kiadis Pharma on Track with European Regulatory Review for ATIR101. Responses Submitted to EMA Day 120 List of Questions". Amsterdam....
- [4] Kiadis Pharma N.V.. (3/14/18). "Press Release: Kiadis Pharma to Present at the Cowen and Company 38th Annual Health Care Conference". Amsterdam....
- [5] Kiadis Pharma N.V.. (3/12/18). "Press Release: Kiadis Pharma Launches a Private Placement of Approximately 2.6 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other Jurisdiction in which Unlawful]". Amsterdam....
- [6] Kiadis Pharma N.V.. (1/16/18). "Press Release: Kiadis Pharma Proposes Former Cipla CEO Subhanu Saxena as New Supervisory Board Member". Amsterdam-Duivendrecht....
- [7] Kiadis Pharma N.V.. (10/10/17). "Press Release: Kiadis Pharma Raises €18.0 Million in a Private Placement of 2.25 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other Jurisdiction where Unlawful]". Amsterdam-Duiv...
- [8] Kiadis Pharma N.V.. (10/9/17). "Press Release: Kiadis Pharma Launches a Private Placement of approximately 2.25 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other Jurisdiction where Unlawful]". Amsterdam-Duive...
- [9] Kiadis Pharma N.V.. (9/27/17). "Press Release: Kiadis Pharma Provides Update on the Marketing Authorization Application Process for ATIR101 in Europe". Amsterdam-Duivendrecht....
- [10] Kiadis Pharma N.V.. (9/5/17). "Press Release: Kiadis Pharma Appoints Karl Hård as Head of Investor Relations and Communications". Amsterdam-Duivendrecht....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top